Primmune Therapeutics, Inc.

Effector Therapeutics, Inc.

Anadys Pharmaceuticals, Inc.

James Richard Appleman

Stephen Evan Webber

Peggy A Thompson

Joyce Tan

Simon Fletcher

The present invention relates to TLR7 agonists according to Formula I and their use in the treatment of diseases such as cancer and infectious disease.

TLR7 agonists

Substituted purines as TLR7 agonists

The present invention relates to TLR7 agonists according to Formula I and their use in the treatment of diseases such as cancer and infectious disease. 

The present disclosure relates to compositions and methods for treating or preventing a fibrotic disorder or disease.

Compositions and methods for treating fibrotic disease

The invention relates to a method for treating disease such as viral infections, tumors, and cancers, comprising administering a TLR7 agonist or TLR7 agonist prodrug according to a cyclical dosing schedule having a dosing period and a resting period. For example, the method encompasses treating disease with: 5-amino-3-(2'-O-acetyl-3&#x2032;-deoxy-&#x3b2;-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one Tosylateaccording to a dosing schedule of every-other-day or a dosing schedule of three consecutive days of dosing followed by four consecutive days of not dosing.

Growing community of inventors

San Diego, CA, United States of America

James Richard Appleman